Peptonic Medical Seeks Extension for Reconstruction

On June 8, 2025, Peptonic Medical AB announced its formal request to the Uppsala District Court for a three-month extension of its ongoing company reconstruction. This move aligns with the company's previously communicated timeline, which anticipated the reconstruction process to be completed within three to six months from the original application date. The extension is intended to allow Peptonic to finalize its reconstruction plan and submit a request for formal plan proceedings under the Swedish Company Reconstruction Act.

The company has revised its forecast due to delays in manufacturing, deliveries, and marketing activities, largely stemming from the reconstruction process and market disruptions following the U.S. administration's implementation of tariffs. These setbacks have particularly affected Peptonic's U.S. expansion efforts, causing a three-month delay. The revised forecast, based on conservative assumptions, anticipates a worst-case scenario where the company and its subsidiaries reach break-even in November 2025. Despite this cautious outlook, Peptonic believes that its planned reconstruction measures are adequate to ensure liquidity through April 2026.

Peptonic's growth strategy continues to focus on the U.S. market, where it has evaluated its distribution structures and tariff-related matters. Simultaneously, the company is intensifying its efforts in the Nordic home market, leveraging new collaborations with agencies specializing in e-commerce to enhance digital sales. These initiatives are expected to bear fruit in the latter half of 2025.

As part of its restructuring measures, Peptonic has entered into agreements for debt-to-equity conversions with Rosland Nordic AB and Fenja Capital Partners A/S, contingent upon the approval of the restructuring plan. Additionally, principal shareholder Maida Vale Capital AB has committed to a SEK 10 million investment, conditional upon the reconstruction plan's approval and the Swedish Securities Council's exemption from the mandatory bid obligation.

Given the current circumstances and the revised forecast, investors may consider holding their positions. The company's strategic initiatives, coupled with its focus on liquidity and market expansion, present a potential for recovery and growth, albeit with inherent risks due to market uncertainties and ongoing reconstruction challenges.